Cargando…

Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden

Poorly differentiated pancreatic neuroendocrine carcinomas (NECs) are rare and aggressive malignancies with rapid disease progression and early widespread metastasis. Given histology similarity, they are commonly treated with platinum-based chemotherapy as small cell lung cancer (SCLC). However, no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Nai-Wen, Tan, Kien-Thiam, Li, Chien-Feng, Kuo, Yu-Hsuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628778/ https://www.ncbi.nlm.nih.gov/pubmed/34898561 http://dx.doi.org/10.3390/curroncol28060388

Ejemplares similares

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
por: Towner, Mary, et al.
Publicado: (2022)

Tumor mutation burden in gastro-entero-pancreatic-neuroendocrine neoplasms
por: Jeong, Sun Young, et al.
Publicado: (2023)

Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab
por: Kadota, Naoki, et al.
Publicado: (2021)

Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma
por: Yang, Shih-Hung, et al.
Publicado: (2021)

Effective treatment of gallbladder neuroendocrine carcinoma with nivolumab
por: Kanda, Shinichiro, et al.
Publicado: (2023)

Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma
por: Yang, Shih-Hung, et al.
Publicado: (2022)

Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma
por: Billon, Emilien, et al.
Publicado: (2019)

A durable complete response resulting from treatment with nivolumab plus ipilimumab for metastatic collecting duct carcinoma of the kidney
por: Funajima, Keisuke, et al.
Publicado: (2023)

Maintenance therapy of low-dose nivolumab, S-1, and leucovorin in metastatic pancreatic adenocarcinoma with a germline mutation of MSH6: A case report
por: Peng, Shang-Hsuan, et al.
Publicado: (2022)

Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
por: Das, Anirban, et al.
Publicado: (2023)

Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide‐induced high tumor mutational burden
por: Cao, Yanshuo, et al.
Publicado: (2020)

Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis
por: Ide, Maako, et al.
Publicado: (2018)

A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient
por: Yatsuda, Yukino, et al.
Publicado: (2020)

Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
por: Al-Toubah, T., et al.
Publicado: (2021)

Complete excision of a large pancreatic neuroendocrine neoplasm
por: Darko, Rudolph, et al.
Publicado: (2018)

Complete and Durable Response After Radiation Therapy to Primary Tumor Site of a Patient With Metastatic Anorectal Mucosal Melanoma With Oligoprogression on Nivolumab
por: Wallington, David G., et al.
Publicado: (2020)

Durable Complete Radiological Response to Nivolumab in Two Heavily Pretreated Western Elderly Patients With Metastatic Gastric Cancer: A Case Report
por: Tirino, Giuseppe, et al.
Publicado: (2020)

Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanoma
por: Tarhini, Ahmad A., et al.
Publicado: (2022)

Post-surgical Pancreatitis Masquerading as Recurrent Neuroendocrine Cancer
por: Adair, Anya, et al.
Publicado: (2010)

Time-trend and recurrence analysis of pancreatic neuroendocrine tumors
por: Kim, Hanbaro, et al.
Publicado: (2019)

Pathological complete response with nivolumab for recurrence of liver metastasis after gastrectomy of gastric cancer
por: Jun, Chen, et al.
Publicado: (2023)

Tumor mutation burden and recurrent tumors in hereditary lung cancer
por: Hsu, Yi‐Chiung, et al.
Publicado: (2019)

Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report
por: Lepir, Tanja, et al.
Publicado: (2019)

Durable benefit and change in TCR clonality with nivolumab in a Lynch syndrome–associated glioma
por: Cabezas-Camarero, Santiago, et al.
Publicado: (2022)

Validation and modification of staging Systems for Poorly Differentiated Pancreatic Neuroendocrine Carcinoma
por: Wang, Haihong, et al.
Publicado: (2020)

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
por: Owen, Dwight H., et al.
Publicado: (2023)

Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge
por: Keane, Fergus, et al.
Publicado: (2023)

Tumor mutational burden is associated with poor outcomes in diffuse glioma
por: Wang, Lihong, et al.
Publicado: (2020)

Nivolumab-Induced Exocrine Pancreatic Insufficiency
por: Sweep, Boudewijn, et al.
Publicado: (2021)

Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors
por: Tan, Qing-quan, et al.
Publicado: (2020)

Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67
por: Genç, C. G., et al.
Publicado: (2018)

Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: A case report
por: Takimoto Sato, Michiko, et al.
Publicado: (2020)

Comparison of the mutational profiles of neuroendocrine breast tumours, invasive ductal carcinomas and pancreatic neuroendocrine carcinomas
por: Karihtala, Peeter, et al.
Publicado: (2022)

Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer
por: Chao, Angel, et al.
Publicado: (2023)

Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy
por: Krammer, Sebastian, et al.
Publicado: (2019)

Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer
por: Lawrence, Ben, et al.
Publicado: (2018)

Case Report: Nivolumab-Induced Autoimmune Pancreatitis
por: Goyal, Preeya, et al.
Publicado: (2021)

Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study
por: Chiang, Nai-Jung, et al.
Publicado: (2022)

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
por: De Divitiis, C., et al.
Publicado: (2016)

Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors
por: Lin, Liang-Yu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2pibhek6k224j9o2l89qpvk5au